Warning! GuruFocus detected
1 Severe warning sign
with MTSR.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Metsera Inc
NAICS : 541714
SIC : 2834
ISIN : US59267L1070
Description
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 35.96 | |||||
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 79.02 | |||||
9-Day RSI | 62.79 | |||||
14-Day RSI | 55.35 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.34 | |||||
Quick Ratio | 5.34 | |||||
Cash Ratio | 5.24 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -30.76 | |||||
ROA % | -17.49 | |||||
ROIC % | -33.3 | |||||
ROC (Joel Greenblatt) % | -25945.79 | |||||
ROCE % | -53.2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -18.72 | |||||
EV-to-EBITDA | -18.73 | |||||
EV-to-FCF | -186.03 | |||||
Price-to-Net-Cash | 12.89 | |||||
Earnings Yield (Greenblatt) % | -5.34 | |||||
FCF Yield % | -0.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MTSR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Metsera Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.513 | ||
Beta | - | ||
3-Year Sharpe Ratio | - | ||
3-Year Sortino Ratio | - | ||
Volatility % | - | ||
14-Day RSI | 55.35 | ||
14-Day ATR ($) | 2.810838 | ||
20-Day SMA ($) | 20.435 | ||
12-1 Month Momentum % | - | ||
52-Week Range ($) | 12.3 - 32.8082 | ||
Shares Outstanding (Mil) | 105.05 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Metsera Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Metsera Inc Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
Metsera Inc Frequently Asked Questions
What is Metsera Inc(MTSR)'s stock price today?
The current price of MTSR is $23.65. The 52 week high of MTSR is $32.81 and 52 week low is $12.30.
When is next earnings date of Metsera Inc(MTSR)?
The next earnings date of Metsera Inc(MTSR) is 2025-05-30 Est..
Does Metsera Inc(MTSR) pay dividends? If so, how much?
Metsera Inc(MTSR) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |